Intraductal carcinoma in situ of breast
ICD-10 D05.1 is a billable code used to indicate a diagnosis of intraductal carcinoma in situ of breast.
Intraductal carcinoma in situ (DCIS) of the breast is a non-invasive form of breast cancer characterized by the presence of abnormal cells within the ducts of the breast tissue. These cells have not invaded surrounding breast tissue, which differentiates DCIS from invasive breast cancer. DCIS is often detected through mammography as microcalcifications and may present with no palpable mass. The condition is considered a precursor to invasive breast cancer, and its management typically involves surgical intervention, such as lumpectomy or mastectomy, often followed by radiation therapy. The risk of progression to invasive cancer varies, with estimates suggesting that approximately 20-30% of untreated DCIS cases may progress to invasive breast cancer within 10 years. Surveillance protocols for patients diagnosed with DCIS include regular clinical examinations, imaging studies, and discussions regarding the potential need for adjuvant therapies. The prognosis for patients with DCIS is generally favorable, particularly with appropriate treatment.
Detailed pathology reports, treatment plans, and follow-up notes.
Diagnosis of DCIS following mammography, treatment planning discussions, and post-operative follow-ups.
Ensure accurate staging and grading of the carcinoma, as well as documentation of any adjuvant therapies.
Clear imaging reports indicating findings suggestive of DCIS, including descriptions of microcalcifications.
Mammography findings leading to biopsy recommendations and imaging follow-ups post-treatment.
Radiologists should provide detailed descriptions of imaging findings to support the diagnosis.
Used for surgical treatment of DCIS.
Operative reports detailing the procedure and findings.
Oncologists should ensure that the surgical approach aligns with the diagnosis.
Used for obtaining tissue for diagnosis of DCIS.
Biopsy reports and imaging studies supporting the need for the procedure.
Radiologists must document the indication for biopsy clearly.
Diagnosing DCIS is crucial as it indicates a risk for developing invasive breast cancer. Early detection and treatment can significantly improve outcomes.
Patients with DCIS should have regular follow-up appointments, typically every 6-12 months, including clinical exams and imaging as recommended by their healthcare provider.
